These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38711513)

  • 1. The purinergic receptor P2X7 as a modulator of viral vector-mediated antigen cross-presentation.
    Longo Y; Mascaraque SM; Andreacchio G; Werner J; Katahira I; De Marchi E; Pegoraro A; Lebbink RJ; Köhrer K; Petzsch P; Tao R; Di Virgilio F; Adinolfi E; Drexler I
    Front Immunol; 2024; 15():1360140. PubMed ID: 38711513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenic cell death of dendritic cells following modified vaccinia virus Ankara infection enhances CD8
    Tappe KA; Budida R; Stankov MV; Frenz T; R Shah H; Volz A; Sutter G; Kalinke U; Behrens GMN
    Eur J Immunol; 2018 Dec; 48(12):2042-2054. PubMed ID: 30259962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified Vaccinia Virus Ankara Can Induce Optimal CD8
    Wong YC; Croft S; Smith SA; Lin LCW; Cukalac T; La Gruta NL; Drexler I; Tscharke DC
    J Virol; 2019 Nov; 93(21):. PubMed ID: 31375596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified vaccinia virus Ankara-infected dendritic cells present CD4+ T-cell epitopes by endogenous major histocompatibility complex class II presentation pathways.
    Thiele F; Tao S; Zhang Y; Muschaweckh A; Zollmann T; Protzer U; Abele R; Drexler I
    J Virol; 2015 Mar; 89(5):2698-709. PubMed ID: 25520512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The DC receptor DNGR-1 mediates cross-priming of CTLs during vaccinia virus infection in mice.
    Iborra S; Izquierdo HM; Martínez-López M; Blanco-Menéndez N; Reis e Sousa C; Sancho D
    J Clin Invest; 2012 May; 122(5):1628-43. PubMed ID: 22505455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo.
    Liu L; Chavan R; Feinberg MB
    BMC Immunol; 2008 Apr; 9():15. PubMed ID: 18412969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified vaccinia virus Ankara-based vaccine vectors induce apoptosis in dendritic cells draining from the skin via both the extrinsic and intrinsic caspase pathways, preventing efficient antigen presentation.
    Guzman E; Cubillos-Zapata C; Cottingham MG; Gilbert SC; Prentice H; Charleston B; Hope JC
    J Virol; 2012 May; 86(10):5452-66. PubMed ID: 22419811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.
    Gómez CE; Perdiguero B; Jiménez V; Filali-Mouhim A; Ghneim K; Haddad EK; Quakkelaar ED; Delaloye J; Harari A; Roger T; Duhen T; Sékaly RP; Melief CJ; Calandra T; Sallusto F; Lanzavecchia A; Wagner R; Pantaleo G; Esteban M
    PLoS One; 2012; 7(4):e35485. PubMed ID: 22536391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD70 encoded by modified vaccinia virus Ankara enhances CD8 T-cell-dependent protective immunity in MHC class II-deficient mice.
    Bathke B; Pätzold J; Kassub R; Giessel R; Lämmermann K; Hinterberger M; Brinkmann K; Chaplin P; Suter M; Hochrein H; Lauterbach H
    Immunology; 2018 Jun; 154(2):285-297. PubMed ID: 29281850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
    Garber DA; O'Mara LA; Zhao J; Gangadhara S; An I; Feinberg MB
    PLoS One; 2009; 4(5):e5445. PubMed ID: 19421328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral sequestration of antigen subverts cross presentation to CD8(+) T cells.
    Tewalt EF; Grant JM; Granger EL; Palmer DC; Heuss ND; Gregerson DS; Restifo NP; Norbury CC
    PLoS Pathog; 2009 May; 5(5):e1000457. PubMed ID: 19478869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
    Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines.
    Gasteiger G; Kastenmuller W; Ljapoci R; Sutter G; Drexler I
    J Virol; 2007 Nov; 81(21):11925-36. PubMed ID: 17699574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model.
    Nörder M; Becker PD; Drexler I; Link C; Erfle V; Guzmán CA
    PLoS One; 2010 Jun; 5(6):e11400. PubMed ID: 20628596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequestration of Late Antigens Within Viral Factories Impairs MVA Vector-Induced Protective Memory CTL Responses.
    Tao S; Tao R; Busch DH; Widera M; Schaal H; Drexler I
    Front Immunol; 2019; 10():2850. PubMed ID: 31867011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine.
    Ramírez JC; Gherardi MM; Esteban M
    J Virol; 2000 Jan; 74(2):923-33. PubMed ID: 10623755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct comparison of antigen production and induction of apoptosis by canarypox virus- and modified vaccinia virus ankara-human immunodeficiency virus vaccine vectors.
    Zhang X; Cassis-Ghavami F; Eller M; Currier J; Slike BM; Chen X; Tartaglia J; Marovich M; Spearman P
    J Virol; 2007 Jul; 81(13):7022-33. PubMed ID: 17409140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses.
    Baur K; Brinkmann K; Schweneker M; Pätzold J; Meisinger-Henschel C; Hermann J; Steigerwald R; Chaplin P; Suter M; Hausmann J
    J Virol; 2010 Sep; 84(17):8743-52. PubMed ID: 20538860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice.
    Altenburg AF; van de Sandt CE; van Trierum SE; De Gruyter HLM; van Run PRWA; Fouchier RAM; Roose K; Saelens X; Volz A; Sutter G; de Vries RD; Rimmelzwaan GF
    J Virol; 2016 Nov; 90(22):10209-10219. PubMed ID: 27581985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stable antigen is most effective for eliciting CD8+ T-cell responses after DNA vaccination and infection with recombinant vaccinia virus in vivo.
    Schliehe C; Bitzer A; van den Broek M; Groettrup M
    J Virol; 2012 Sep; 86(18):9782-93. PubMed ID: 22761378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.